Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-10 (Canceled)

11. (New) A method for treating fibrotic diseases which are not caused by inflammatory responses to foreign matters, comprising administering at least one proteasome inhibitor to a patient in need of such treatment.

12. (New) A method for treating cardiac fibrosis caused by overload, a liver fibrosis caused by congestion, a kidney fibrosis caused by high pressure or a joint fibrosis in case of a joint malposition, comprising administering at least one proteasome inhibitor to a patient in need of such treatment.

13. (New) The method according to claim 12, wherein said cardiac fibrosis is caused by overload under chronic pressure stress in arterial hypertension and/or by overload in compensatory hyperkinesia of the intact residual myocardium in case of myocardial infarction.

14. (New) The method according to claim 12, wherein said cardiac fibrosis is treatable with ACE inhibitors, AT-1-antagonists and/or endothelin receptor antagonists.

15. (New) The method according to claim 11, wherein said patient is administered at least one proteasome inhibitor in a dose of approximately 0.5 μg/kg body weight to approximately 0.5 mg/kg body weight.

16. (New) The method according to claim 15, wherein said patient is administered at least one proteasome inhibitor in a dose of approximately 1 μg/kg body weight to approximately 0.1 mg/kg body weight.

17. (New) The method according to claim 16, wherein said patient is administered at least one proteasome inhibitor in a dose of approximately 0.01 mg/kg body weight to approximately 0.1 mg/kg body weight.

18. (New) The method according to claim 11, wherein the fibrotic diseases are fibrotic organ diseases.

19. (New) The method according to claim 18, wherein said fibrotic organ diseases are diseases of the lung, liver, skin, joints, skeleton and/or glands.

20. (New) The method according to claim 18, wherein said fibrotic organ diseases are diseases of the cardiovascular system.

21. (New) The method according to claim 11, wherein the proteasome inhibitor is selected from the group consisting of a low-molecular organic compound, an N-terminal threonine protease inhibitor, a modified peptide inhibitor, and MG132.

22. (New) The method according to claim 21, wherein said modified peptide inhibitor is a peptide boronate or a peptide aldehyde.

23. (New) The method according to claim 21, wherein the proteasome inhibitor is selected from the group consisting of a threonine protease inhibitor, a serine protease inhibitor, a cysteine protease inhibitor, a gene expression inhibitor of the proteasomal system and a binding protein or binding peptide directed against at least one component of the proteasomal system.

24. (New) The method according to claim 23, wherein said binding protein or binding peptide is directed against ubiquitin and/or against the proteasome.

25. (New) The method according to claim 21, wherein the proteasome inhibitor is selected from the group consisting of a peptide aldehyde, a peptide boronate, a peptide vinyl sulfone, a peptide epoxyketone, a lactacystine, a peptide alpha keto-aldehyde, an alpha-ketoamide, an indanone peptide, a polyalkylene aldehyde, a polyphenol, in particular a cathechin-3-gallate, a nucleic acid directed against at least one component of the proteasomal system and an antibody or binding-reactive part or derivative thereof, directed against at least one component of the proteasomal system.

26. (New) The method according to claim 21, wherein the proteasome inhibitor is selected from the group consisting of Z-Leu-Leu-Leu-al (MG132), Z-Ile-Glu(OtBu)-Ala-Leu-al (PSI), CEP1612, pyrazylcarbonyl-Phe-Leu-boronate (PS-341), dansyl-Phe-Leu-boronate (DFLB), morpholino-naphthylalanine-Leu-boronate (MG273), NIP-Leu_3-vinylsulfone (NLVS), Tyr-Leu_3-VS, NIP-Leu-Leu-Asn-VS, Ada-Tyr-Ahx_3-Leu_3-VS, Ada-Lys(Bio)-Ahx_3-Leu_3-VS, Ac(Me)-Ile-Ile-Thr-Leu-EX (epoxomicin), dihydroeponemycin, lactacystine, clasto-lactacystine-beta-lactone (omuralide), PS-519, Ac-Leu-Leu-Nle-al (ALLN), 3,4-dichloroisocoumarine (DCI), 4-(2-aminoethyl)-benzenesulfonyl fluoride (Pefablock SC), TMC-95A, gliotoxin, (-)-epigallocatechin-3-gallate (EGCG), ritonavir, lovastatin, aclacinomicin A (Aclarubicin), cyclosporin, an anti-sense-RNA or a double-stranded RNA (dsRNA) against a proteasome encoding sequence, a triplex forming oligonucleotide against a proteasome encoding sequence and a knock-out construct against a proteasome encoding sequence, wherein Z is a benzyloxycarbonyl group, al is an aldehyde group, VS is a vinyl sulfone group, NIP is a 3-nitro-4-hydroxy-5-iodophenylacetate group, and Bio is a biotin group.